CD56在急性髓系白血病患者中的预后价值：一项荟萃分析。
Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis.
作者信息
Xu Shuangnian, Li Xi, Zhang Jianmin, Chen Jieping
机构信息
Center for Hematology, Southwest Hospital, Third Military Medical University, Chongqing, China.
出版信息
J Cancer Res Clin Oncol. 2015 Oct;141(10):1859-70. doi: 10.1007/s00432-015-1977-3. Epub 2015 Apr 30.
PURPOSE
Extensive studies have investigated the prognostic value of CD56 for patients with acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta-analysis is to resolve this controversial issue.
METHODS
A systematic search of PubMed, Embase, Cochrane Library, and CBM was performed to identify studies that assessed the prognostic value of CD56 in AML patients. Pooled hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS) and pooled odds ratio (OR) with 95 % CIs for complete remission rate (CRR) and relapse rate (RR) were calculated.
RESULTS
Totally, 32 studies with 4074 patients were included. For AML with t(8;21) translocation, CD56 overexpression was associated with shorter OS (HR 2.22; 95 % CI 1.30-3.78) and DFS (HR 2.63; 95 % CI 1.10-6.29) and increased RR (OR 3.29; 95 % CI 1.67-6.48), but did not affect CRR (OR 0.94; 95 % CI 0.49-1.80). For AML with t(15;17) translocation, CD56 overexpression was associated with shorter OS (HR 2.43; 95 % CI 1.66-3.57) and DFS (HR 4.27; 95 % CI 1.15-15.78), increased RR (OR 3.11; 95 % CI 2.01-4.81), and decreased CRR (OR 0.42; 95 % CI 0.25-0.72). For AML as a whole, CD56 overexpression was associated with shorter OS (HR 1.74; 95 % CI 1.38-2.19) and DFS (HR 2.38; 95 % CI 1.87-3.02), increased RR (OR 5.19; 95 % CI 2.84-9.48), and decreased CRR (OR 0.62; 95 % CI 0.41-0.96).
CONCLUSIONS
This meta-analysis indicated that CD56 overexpression may be an adverse prognostic factor for AML.
目的
大量研究探讨了CD56对急性髓系白血病（AML）患者的预后价值，但结果仍无定论。本荟萃分析的目的是解决这一有争议的问题。
方法
系统检索PubMed、Embase、Cochrane图书馆和中国生物医学文献数据库，以确定评估CD56在AML患者中预后价值的研究。计算总生存（OS）和无病生存（DFS）的合并风险比（HRs）及95%置信区间（CIs），以及完全缓解率（CRR）和复发率（RR）的合并比值比（OR）及95% CIs。
结果
共纳入32项研究，涉及4074例患者。对于伴有t(8;21)易位的AML，CD56过表达与较短的OS（HR 2.22；95% CI 1.30 - 3.78）和DFS（HR 2.63；95% CI 1.10 - 6.29）以及RR增加（OR 3.29；95% CI 1.67 - 6.48）相关，但不影响CRR（OR 0.94；95% CI 0.49 - 1.80）。对于伴有t(15;17)易位的AML，CD56过表达与较短的OS（HR 2.43；95% CI 1.66 - 3.57）和DFS（HR 4.27；95% CI 1.15 - 15.78）、RR增加（OR 3.11；95% CI 2.01 - 4.81）以及CRR降低（OR 0.42；95% CI 0.25 - 0.72）相关。对于整体AML，CD56过表达与较短的OS（HR 1.74；95% CI 1.38 - 2.19）和DFS（HR 2.38；95% CI 1.87 - 3.02）、RR增加（OR 5.19；95% CI 2.84 - 9.48）以及CRR降低（OR 0.62；95% CI 0.41 - 0.96）相关。
结论
本荟萃分析表明，CD56过表达可能是AML的不良预后因素。
Zotero 插件